Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 MillionGlobeNewsWire · 5 days ago
Head to Head Review: Surrozen (NASDAQ:SRZN) and Prelude Therapeutics (NASDAQ:PRLD)Defense World · Oct 12, 2026
Surrozen (NASDAQ:SRZN) & Whitehawk Therapeutics (NASDAQ:WHWK) Financial ComparisonDefense World · Oct 12, 2026
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular EdemaGlobeNewsWire · Oct 2, 2026
Surrozen Gains Momentum as FDA Submission Opens Path for Lead TherapyBenzinga · Sep 24, 2026
Surrozen, Inc. (SRZN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 16, 2026Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.29 | -$0.41 | Beat |
| May 6, 2026 | -$1.39 | -$11.65 | Miss |
| Mar 23, 2026 | -$1.29 | -$19.13 | Miss |
| Nov 7, 2025 | -$1.17 | -$8.36 | Miss |
| Aug 8, 2025 | -$1.23 | -$1.14 | Beat |
| May 9, 2025 | -$1.09 | -$7.43 | Miss |